Jump to content

Mycobacterium

This is a good article. Click here for more information.
From Wikipedia, the free encyclopedia
(Redirected from Mycobacterial disease)

Mycobacterium
TEM micrograph of M. tuberculosis
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Actinomycetota
Class: Actinomycetia
Order: Mycobacteriales
Family: Mycobacteriaceae
Genus: Mycobacterium
Lehmann & Neumann 1896[1]
Species

Over 190 species, see LPSN

Synonyms[2]
  • Mycolicibacterium Gupta et al. 2018
  • Mycolicibacillus Gupta et al. 2018
  • Mycolicibacter Gupta et al. 2018
  • Mycobacteroides Gupta et al. 2018

Mycobacterium is a genus of over 190 species in the phylum Actinomycetota, assigned its own family, Mycobacteriaceae. This genus includes pathogens known to cause serious diseases in mammals, including tuberculosis (M. tuberculosis) and leprosy (M. leprae) in humans. The Greek prefix myco- means 'fungus', alluding to this genus' mold-like colony surfaces.[3] Since this genus has cell walls with a waxy lipid-rich outer layer containing high concentrations of mycolic acid,[4] acid-fast staining is used to emphasize their resistance to acids, compared to other cell types.[5]

Mycobacterial species are generally aerobic, non-motile, and capable of growing with minimal nutrition. The genus is divided based on each species' pigment production and growth rate.[6] While most Mycobacterium species are non-pathogenic, the genus' characteristic complex cell wall contributes to evasion from host defenses.[7]

Microbiology

[edit]

Morphology

[edit]
Model of the Mycobacterium spp. cell envelope with 3-D protein structures

Mycobacteria are aerobic with 0.2-0.6 μm wide and 1.0-10 μm long rod shapes. They are generally non-motile, except for the species Mycobacterium marinum, which has been shown to be motile within macrophages.[8] Mycobacteria possess capsules and most do not form endospores. M. marinum and perhaps M. bovis have been shown to sporulate;[9] however, this has been contested by further research.[10] The distinguishing characteristic of all Mycobacterium species is a thick, hydrophobic, and mycolic acid-rich cell wall made of peptidoglycan and arabinogalactan, with these unique components offering targets for new tuberculosis drugs.[11]

Physiology

[edit]

Many Mycobacterium species readily grow with minimal nutrients, using ammonia and/or amino acids as nitrogen sources and glycerol as a carbon source in the presence of mineral salts. Temperatures for optimal growth vary between species and media conditions, ranging from 25 to 45 °C.[6]

Most Mycobacterium species, including most clinically relevant species, can be cultured in blood agar.[12] However, some species grow very slowly due to extremely long reproductive cycles, such as M. leprae requiring 12 days per division cycle compared to 20 minutes for some E. coli strains.[13]

Ecology

[edit]

Whereas Mycobacterium tuberculosis and M. leprae are pathogenic, most mycobacteria do not cause disease unless they enter skin lesions of those with pulmonary and/or immune dysfunction, despite being widespread across aquatic and terrestrial environments. Through biofilm formation, cell wall resistance to chlorine, and association with amoebas, mycobacteria can survive a variety of environmental stressors. The agar media used for most water testing does not support the growth of mycobacteria, allowing it to go undetected in municipal and hospital systems.[14]

Genomics

[edit]

Hundreds of Mycobacterium genomes have been completely sequenced.[15]

The genome sizes of mycobacteria range from relatively small ones (e.g. in M. leprae) to quite large ones, such as that as M. vulneris, encoding 6,653 proteins, larger than the ~6000 proteins of eukaryotic yeast.[16]

Protein-Coding Genomic Information
Organism Number of Protein Coding Genes
M. intracellulare 5,289[17]
M. colombiense 5,084[18]
M. leprae 1,603[19]
M. tuberculosis 3,995[19]
M. smegmatis 6,602[20]
M. chelonae 4,948[21]

Pathogenicity

[edit]

Mycobacterium tuberculosis complex

[edit]

Mycobacterium tuberculosis can remain latent in human hosts for decades after an initial infection, allowing it to continue infecting others. It has been estimated that a third of the world population has latent tuberculosis (TB).[22] M. tuberculosis has many virulence factors, which can be divided across lipid and fatty acid metabolism, cell envelope proteins, macrophage inhibitors, kinase proteins, proteases, metal-transporter proteins, and gene expression regulators.[23] Several lineages such as M. t. var. bovis (bovine TB) were considered separate species in the M, tuberculosis complex until they were finally merged into the main species in 2018.[24]

Leprosy

[edit]

The development of Leprosy is caused by infection with either Mycobacterium leprae or Mycobacterium lepromatosis, two closely related bacteria. Roughly 200,000 new cases of infection are reported each year, and 80% of new cases are reported in Brazil, India, and Indonesia.[25] M. leprae infection localizes within the skin macrophages and Schwann cells found in peripheral nerve tissue.

Nontuberculosis Mycobacteria

[edit]
Orthologous proteins found in each species (based on OMA identifiers). Unique proteins for each species are localized in the outer section for each species.

Nontuberculosis Mycobacteria (NTM), which exclude M. tuberculosis, M. leprae, and M. lepromatosis, can infect mammalian hosts. These bacteria are referred to as "atypical mycobacteria." Although person-to-person transmission is rare, transmission of M. abscessus has been observed between patients with cystic fibrosis.[26] The four primary diseases observed in humans are chronic pulmonary disease, disseminated disease in immunocompromised patients, skin and soft tissue infections, and superficial lymphadenitis. 80-90% of recorded NTM infections manifest as pulmonary diseases.[27]

M. abscessus is the most virulent rapidly-growing mycobacterium (RGM), as well as the leading cause of RGM based pulmonary infections. Although it has been traditionally viewed as an opportunistic pathogen like other NTMs, analysis of various virulence factors (VFs) have shifted this view to that of a true pathogen. This is due to the presence of known mycobacterial VFs and other non-mycobacterial VFs found in other prokaryotic pathogens.[27]

Virulence factors

[edit]

Mycobacteria have cell walls with peptidoglycan, arabinogalactan, and mycolic acid; a waxy outer mycomembrane of mycolic acid; and an outermost capsule of glucans and secreted proteins for virulence. It constantly remodels these layers to survive in stressful environments and avoid host immune defenses. This cell wall structure results in colony surfaces resembling fungi, leading to the genus' use of the Greek prefix myco-.[28] This unique structure makes penicillins ineffective, instead requiring a multi-drug antibiotic treatment of isoniazid to inhibit mycolic acid synthesis, rifampicin to interfere with transcription, ethambutol to hinder arabinogalactan synthesis, and pyrazinamide to impede Coenzyme A synthesis.[7]

Mycobacterial Infection Information
Organism Common Symptoms of Infection Known Treatments Reported Cases (Region, Year)
M. tuberculosis Fatigue, weight loss, fever, hemoptysis, chest pain.[29] isoniazid INH, rifampin, pyrazinamide, ethambutol.[30] 1.6 Million (Global, 2021)[31]
M. leprae

M. lepromatosis

Skin discoloration, nodule development, dry skin, loss of eyebrows and/or eyelashes, numbness, nosebleeds, paralysis, blindness, nerve pain.[32] dapson, rifampicin, clofazimine.[32] 133,802 (Global, 2021)[33]
M. avium complex Tender skin, development of boils or pus-filled vesicles, fevers, chills, muscle aches.[34] clarithromycin, azithromycin, amikacin, cefoxitin, imipenem.[35] 3000 (US, Annual estimated)[36]
M. abscessus complex Coughing, hemoptysis, fever, cavitary lesions.[37] clarithromycin, amikacin, cefoxitin, imipenem.[37] Unknown

History

[edit]
Cladogram of Key Species

Mycobacteria have historically been categorized through phenotypic testing, such as the Runyon classification of analyzing growth rate and production of yellow/orange carotenoid pigments. Group I contains photochromogens (pigment production induced by light), Group II comprises scotochromogens (constitutive pigment production), and the non-chromogens of Groups III and IV have a pale yellow/tan pigment, regardless of light exposure. Group IV species are "rapidly-growing" mycobacteria compared to the "slowly-growing" Group III species because samples grow into visible colonies in less than seven days.[6]

Because the International Code of Nomenclature of Prokaryotes (ICNP) currently recognizes 195 Mycobacterium species, classification and identification systems now rely on DNA sequencing and computational phylogenetics. The major disease-causing groups are the M. tuberculosis complex (tuberculosis), M. avium complex (mycobacterium avium-intracellulare infection), M. leprae and M. lepromatosis (leprosy), and M. abscessus (chronic lung infection).[3]

Microbiologist Enrico Tortoli has constructed a phylogenetic tree of the genus' key species based on the earlier genetic sequencing of Rogall, et al. (1990), alongside new phylogentic trees based on Tortoli's 2017 sequencing of 148 Mycobacterium species:[38]

  • Phylogenetic tree of slowly-growing members of the Mycobacterium genus
    Phylogenetic tree of slowly-growing members of the Mycobacterium genus
  • Phylogenetic tree of rapidly-growing members of the Mycobacterium genus, alongside the M. terrae complex.[39]
    Phylogenetic tree of rapidly-growing members of the Mycobacterium genus, alongside the M. terrae complex.[39]

Proposed division of the genus

[edit]

Gupta et al. have proposed dividing Mycobacterium into five genera, based on an analysis of 150 species in this genus. Due to controversy over complicating clinical diagnoses and treatment, all of the renamed species have retained their original identity in the Mycobacterium genus as a valid taxonomic synonym:[40][41]

  • Mycobacterium based on the Slowly-Growing Tuberculosis-Simiae clade
  • Mycobacteroides based on the Rapidly-Growing Abscessus-Chelonae clade
  • Mycolicibacillus based on the Slowly-Growing Triviale clade
  • Mycolicibacter based on the Slowly-Growing Terrae clade
  • Mycolicibacterium based on the Rapidly-Growing Fortuitum-Vaccae clade
Further information: Bacterial taxonomy § Pathology vs. phylogeny

Diagnosis

[edit]

The two most common methods for visualizing these acid-fast bacilli as bright red against a blue background are the Ziehl-Neelsen stain and modified Kinyoun stain. Fite's stain is used to color M. leprae cells as pink against a blue background. Rapid Modified Auramine O Fluorescent staining has specific binding to slowly-growing mycobacteria for yellow staining against a dark background. Newer methods include Gomori-Methenamine Silver staining and Perioidic Acid Schiff staining to color Mycobacterium avium complex (MAC) cells black and pink, respectively.[5]

While some mycobacteria can take up to eight weeks to grow visible colonies from a cultured sample, most clinically relevant species will grow within the first four weeks, allowing physicians to consider alternative causes if negative readings continue past the first month.[42] Growth media include Löwenstein–Jensen medium and mycobacteria growth indicator tube (MGIT).

  • Mycobacterium tuberculosis on Ziehl-Neelsen stain
    Mycobacterium tuberculosis on Ziehl-Neelsen stain
  • Slant tubes of Löwenstein-Jensen medium.[note 1]
    Slant tubes of Löwenstein-Jensen medium.[note 1]
  • MGIT samples emitting fluorescence in ultraviolet light
    MGIT samples emitting fluorescence in ultraviolet light

Mycobacteriophages

[edit]

Mycobacteria can be infected by mycobacteriophages, a class of viruses with high specificity for their targets. By hijacking the cellular machinery of mycobacteria to produce additional phages, such viruses can be used in phage therapy for eukaryotic hosts, as they would die alongside the mycobacteria. Since only some mycobacteriophages are capable of penetrating the M. tuberculosis membrane, the viral DNA may be delivered through artificial liposomes because bacteria uptake, transcribe, and translate foreign DNA into proteins.[43]

Mycosides

[edit]

Mycosides are glycolipids isolated from Mycobacterium species with Mycoside A found in photochromogenic strains, Mycoside B in bovine strains, and Mycoside C in avian strains.[44] Different forms of Mycoside C have varying success as a receptor to inactivate mycobacteriophages.[45] Replacement of the gene encoding mycocerosic acid synthase in M. bovis prevents formation of mycosides.[46]

Notes

[edit]
  1. ^ From left to right in image of slant tubes of Löwenstein-Jensen medium:
    - Negative control
    - M. tuberculosis: Dry-appearing colonies
    - Mycobacterium avium complex: Wet-appearing colonies
    - M. gordonae: Yellowish colonies

References

[edit]
  1. ^ Lehmann KB, Neumann R (1896). Atlas und Grundriss der Bakteriologie und Lehrbuch der speziellen bakteriologischen Diagnostik [Atlas and Outline of Bacteriology and Textbook of Special Bacteriological Diagnostics] (1st ed.). München: J.F. Lehmann.
  2. ^ Euzéby JP, Parte AC. "Mycobacterium". List of Prokaryotic names with Standing in Nomenclature (LPSN). Retrieved June 16, 2021.[permanent dead link‍]
  3. ^ a b Mycobacteria: Health Advisory (PDF). Environmental Protection Agency (Report). August 1999.
  4. ^ Batt SM, Minnikin DE, Besra GS (May 2020). "The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host's immune system". The Biochemical Journal. 477 (10): 1983–2006. doi:10.1042/BCJ20200194. PMC 7261415. PMID 32470138.
  5. ^ a b Pennington KM, Vu A, Challener D, Rivera CG, Shweta FN, Zeuli JD, Temesgen Z (August 2021). "Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease". Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 24: 100244. doi:10.1016/j.jctube.2021.100244. PMC 8135042. PMID 34036184.
  6. ^ a b c Forbes BA, Hall GS, Miller MB, Novak SM, Rowlinson MC, Salfinger M, et al. (April 2018). "Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria". Clinical Microbiology Reviews. 31 (2): e00038–17. doi:10.1128/CMR.00038-17. PMC 5967691. PMID 29386234.
  7. ^ a b Dulberger CL, Rubin EJ, Boutte CC (January 2020). "The mycobacterial cell envelope - a moving target". Nature Reviews. Microbiology. 18 (1): 47–59. doi:10.1038/s41579-019-0273-7. PMID 31728063. S2CID 208020338.
  8. ^ Stamm LM, Morisaki JH, Gao LY, Jeng RL, McDonald KL, Roth R, et al. (November 2003). "Mycobacterium marinum escapes from phagosomes and is propelled by actin-based motility". The Journal of Experimental Medicine. 198 (9): 1361–1368. doi:10.1084/jem.20031072. PMC 2194249. PMID 14597736.
  9. ^ Ghosh J, Larsson P, Singh B, Pettersson BM, Islam NM, Sarkar SN, et al. (June 2009). "Sporulation in mycobacteria". Proceedings of the National Academy of Sciences of the United States of America. 106 (26): 10781–10786. Bibcode:2009PNAS..10610781G. doi:10.1073/pnas.0904104106. PMC 2705590. PMID 19541637.
  10. ^ Traag BA, Driks A, Stragier P, Bitter W, Broussard G, Hatfull G, et al. (January 2010). "Do mycobacteria produce endospores?". Proceedings of the National Academy of Sciences of the United States of America. 107 (2): 878–881. Bibcode:2010PNAS..107..878T. doi:10.1073/pnas.0911299107. PMC 2818926. PMID 20080769.
  11. ^ Bhamidi S (2009). "Mycobacterial Cell Wall Arabinogalactan". Bacterial Polysaccharides: Current Innovations and Future Trends. Caister Academic Press. ISBN 978-1-904455-45-5.
  12. ^ Lagier JC, Edouard S, Pagnier I, Mediannikov O, Drancourt M, Raoult D (January 2015). "Current and past strategies for bacterial culture in clinical microbiology". Clinical Microbiology Reviews. 28 (1): 208–236. doi:10.1128/CMR.00110-14. PMC 4284306. PMID 25567228.
  13. ^ Shepard CC, Mcrae DH (February 1965). "Mycobacterium leprae in Mice: Minimal Infectious Dose, Relationship Between Staining Quality and Infectivity, and Effect of Cortisone". Journal of Bacteriology. 89 (2): 365–372. doi:10.1128/jb.89.2.365-372.1965. PMC 305516. PMID 14255702.
  14. ^ Vaerewijck MJ, Huys G, Palomino JC, Swings J, Portaels F (November 2005). "Mycobacteria in drinking water distribution systems: ecology and significance for human health". FEMS Microbiology Reviews. 29 (5): 911–934. doi:10.1016/j.femsre.2005.02.001. PMID 16219512.
  15. ^ "JGI GOLD | Projects". gold.jgi.doe.gov. Retrieved 2023-05-13.
  16. ^ Croce O, Robert C, Raoult D, Drancourt M (May 2014). "Draft Genome Sequence of Mycobacterium vulneris DSM 45247T". Genome Announcements. 2 (3). doi:10.1128/genomeA.00370-14. PMC 4014686. PMID 24812218.
  17. ^ "UniProt". www.uniprot.org. Retrieved 2023-05-07.
  18. ^ "UniProt". www.uniprot.org. Retrieved 2023-05-07.
  19. ^ a b "UniProt". www.uniprot.org. Retrieved 2023-05-07.
  20. ^ "UniProt". www.uniprot.org. Retrieved 2023-05-07.
  21. ^ "UniProt". www.uniprot.org. Retrieved 2023-05-07.
  22. ^ Getahun H, Matteelli A, Chaisson RE, Raviglione M (May 2015). "Latent Mycobacterium tuberculosis infection". The New England Journal of Medicine. 372 (22): 2127–2135. doi:10.1056/NEJMra1405427. PMID 26017823.
  23. ^ Forrellad MA, Klepp LI, Gioffré A, Sabio y García J, Morbidoni HR, de la Paz Santangelo M, et al. (January 2013). "Virulence factors of the Mycobacterium tuberculosis complex". Virulence. 4 (1): 3–66. doi:10.4161/viru.22329. PMC 3544749. PMID 23076359.
  24. ^ Riojas, Marco A.; McGough, Katya J.; Rider-Riojas, Cristin J.; Rastogi, Nalin; Hazbón, Manzour Hernando (1 January 2018). "Phylogenomic analysis of the species of the Mycobacterium tuberculosis complex demonstrates that Mycobacterium africanum, Mycobacterium bovis, Mycobacterium caprae, Mycobacterium microti and Mycobacterium pinnipedii are later heterotypic synonyms of Mycobacterium tuberculosis". International Journal of Systematic and Evolutionary Microbiology. 68 (1): 324–332. doi:10.1099/ijsem.0.002507. PMID 29205127.
  25. ^ Sugawara-Mikami M, Tanigawa K, Kawashima A, Kiriya M, Nakamura Y, Fujiwara Y, Suzuki K (December 2022). "Pathogenicity and virulence of Mycobacterium leprae". Virulence. 13 (1): 1985–2011. doi:10.1080/21505594.2022.2141987. PMC 9635560. PMID 36326715.
  26. ^ "Nontuberculous Mycobacteria (NTM) Infections | HAI | CDC". www.cdc.gov. 2019-08-12. Retrieved 2023-04-28.
  27. ^ a b To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V (August 2020). "General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus". Journal of Clinical Medicine. 9 (8): 2541. doi:10.3390/jcm9082541. PMC 7463534. PMID 32781595.
  28. ^ "Mycobacteria: Health Advisory EPA-822-B-01-007" (PDF). epa.gov. US Environmental Protection Agency (EPA). August 1999. p. 2. Retrieved 10 March 2023.
  29. ^ "Fact Sheets | General | Tuberculosis: General Information | TB | CDC". www.cdc.gov. 2022-08-17. Retrieved 2023-04-25.
  30. ^ "Diagnosing and Treating Tuberculosis". American Lung Association. Retrieved 2023-04-25.
  31. ^ "Global Tuberculosis Report 2022". www.who.int. Retrieved 2023-05-07.
  32. ^ a b "Signs and Symptoms | Hansen's Disease (Leprosy) | CDC". www.cdc.gov. 2018-10-22. Retrieved 2023-04-25.
  33. ^ "Global leprosy (Hansen disease) update, 2021: moving towards interruption of transmission". www.who.int. Retrieved 2023-05-07.
  34. ^ "Mycobacterium abscessus in Healthcare Settings | HAI | CDC". www.cdc.gov. 2021-11-15. Retrieved 2023-04-27.
  35. ^ Weng YW, Huang CK, Sy CL, Wu KS, Tsai HC, Lee SS (June 2020). "Treatment for Mycobacterium abscessus complex-lung disease". Journal of the Formosan Medical Association = Taiwan Yi Zhi. Consensus Statement of Nontuberculous Mycobacterial Lung Disease in Taiwan. 119 (Suppl 1): S58–S66. doi:10.1016/j.jfma.2020.05.028. PMID 32527504. S2CID 219604813.
  36. ^ Scholar E (2007-01-01), Enna SJ, Bylund DB (eds.), "Mycobacterium Avium-Intracellulare Infections", xPharm: The Comprehensive Pharmacology Reference, New York: Elsevier, pp. 1–5, doi:10.1016/b978-008055232-3.60891-8, ISBN 978-0-08-055232-3, retrieved 2023-05-07
  37. ^ a b Huang YC, Liu MF, Shen GH, Lin CF, Kao CC, Liu PY, Shi ZY (October 2010). "Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. 43 (5): 401–406. doi:10.1016/S1684-1182(10)60063-1. PMID 21075707.
  38. ^ Tortoli E (2019-01-10). "Chapter 1 - The Taxonomy of the Genus Mycobacterium". In Velayati AA, Farnia P (eds.). Nontuberculous Mycobacteria (NTM). Academic Press. pp. 1–10. doi:10.1016/B978-0-12-814692-7.00001-2. ISBN 978-0-12-814692-7. S2CID 92810288.
  39. ^ Tortoli E, Fedrizzi T, Meehan CJ, Trovato A, Grottola A, Giacobazzi E, et al. (December 2017). "The new phylogeny of the genus Mycobacterium: The old and the news". Infection, Genetics and Evolution. 56: 19–25. Bibcode:2017InfGE..56...19T. doi:10.1016/j.meegid.2017.10.013. PMID 29030295.
  40. ^ Gupta RS, Lo B, Son J (2018). "Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera". Frontiers in Microbiology. 9: 67. doi:10.3389/fmicb.2018.00067. PMC 5819568. PMID 29497402.
  41. ^ Tortoli E, Brown-Elliott BA, Chalmers JD, Cirillo DM, Daley CL, Emler S, et al. (July 2019). "Same meat, different gravy: ignore the new names of mycobacteria". The European Respiratory Journal. 54 (1): 1900795. doi:10.1183/13993003.00795-2019. PMID 31296783.
  42. ^ Ogwang S, Mubiri P, Bark CM, Joloba ML, Boom WH, Johnson JL (October 2015). "Incubation time of Mycobacterium tuberculosis complex sputum cultures in BACTEC MGIT 960: 4weeks of negative culture is enough for physicians to consider alternative diagnoses". Diagnostic Microbiology and Infectious Disease. 83 (2): 162–164. doi:10.1016/j.diagmicrobio.2015.07.002. PMC 4573350. PMID 26239846.
  43. ^ Azimi T, Mosadegh M, Nasiri MJ, Sabour S, Karimaei S, Nasser A (2019-09-17). "Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review". Infection and Drug Resistance. 12: 2943–2959. doi:10.2147/IDR.S218638. PMC 6756577. PMID 31571947.
  44. ^ Smith DW, Randall HM, Maclennan AP, Lederer E (June 1960). "Mycosides: a new class of type-specific glycolipids of Mycobacteria". Nature. 186 (4728): 887–888. Bibcode:1960Natur.186..887S. doi:10.1038/186887a0. PMID 13831939. S2CID 4149360.
  45. ^ Goren MB, McClatchy JK, Martens B, Brokl O (June 1972). "Mycosides C: behavior as receptor site substance for mycobacteriophage D4". Journal of Virology. 9 (6): 999–1003. doi:10.1128/jvi.9.6.999-1003.1972. PMC 356406. PMID 4113889.
  46. ^ Azad AK, Sirakova TD, Rogers LM, Kolattukudy PE (May 1996). "Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides". Proceedings of the National Academy of Sciences of the United States of America. 93 (10): 4787–4792. Bibcode:1996PNAS...93.4787A. doi:10.1073/pnas.93.10.4787. PMC 39357. PMID 8643481.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mycobacterium&oldid=1256721761"